Neurological Disorder Diagnostics Market Analysis & Forecast: 2026-2033

Neurological Disorder Diagnostics Market Size and Forecast – 2026 to 2033

The Neurological Disorder Diagnostics Market is estimated to be valued at USD 13.76 Bn in 2026 and is expected to reach USD 15.87 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 9.1% from 2026 to 2033.

Key Takeaways

• By Technology, Imaging holds the largest market share of 53.3% in 2026 owing to its rising prevalence of neurological disorders.
• By Disease Indication, Genetic Neurological Disorder expected to hold largest market share of 43.5% in 2026 owing to the advancements in genetic testing technologies.
• By End User, Hospitals & Clinics acquired the 42.9% share of the market in 2026 owing to the comprehensive diagnostic capabilities.
• By Region, North America dominates the neurological disorder diagnostics market with an estimated share of 41.8% in 2026, owing to the significant healthcare spending & research investment.

Market Overview

The market for neurological disorder diagnostics is growing quickly as the prevalence of neurological and neurodegenerative disorders rises and the population ages, alongside increased awareness of early detection and precision medicine. Genetic tests, advanced imaging technologies, and AI-powered diagnostic tools are making things more accurate and faster. To meet the needs of patients, hospitals, clinics, and specialized diagnostic centers are adding more services. North America and Europe are the market leaders due to they have strong healthcare systems, research funding, and new technologies. Emerging regions are progressively starting to use these solutions as well.

Current Events and Its Impact on the Neurological Disorder Diagnostics Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

How is AI (Artificial Intelligence) transforming the Neurological Disorder Diagnostics Industry?

Artificial intelligence (AI) is changing the way neurological disorders are diagnosed by making it possible to analyze complicated brain data more quickly, accurately, and objectively. AI algorithms can process an enormous amount of neuroimaging, electrophysiological, and clinical data to find small patterns that are linked to diseases like Alzheimer's, Parkinson's, epilepsy, and multiple sclerosis.

For instance, in November 2025, Royal Philips and Cortechs.ai, a leader in quantitative neuroimaging, worked together. The partnership will add Cortechs.ai's AI-powered neuroimaging analytics directly to Philips' MRI systems. This will make it possible to assess brain health faster, more objectively, and more consistently.

Segmental Insights 

To learn more about this report, Download Free Sample

Neurological Disorder Diagnostics Market Insights, By Technology: Imaging contributes the highest share of the market owing to its integration of AI and advanced analytics.

Imaging holds the largest market share of 53.3% in 2026. The neurological disorder diagnostics market is growing owing to improvements in MRI, CT, PET, and hybrid imaging systems that make them more accurate and allow for earlier detection. The increasing prevalence of neurological conditions and older people increases the need for clinical services. AI and advanced analytics help doctors understand results faster and make fewer mistakes. Healthcare providers focus on early diagnosis and precision medicine. They also work to improve the capabilities of hospitals and clinics and use supportive reimbursement policies to encourage more people to use these services. Ongoing research also encourages new ideas and broader use. In September 2025, GE HealthCare announced that it would buy icometrix, an AI-powered brain imaging company, to meet the growing demand for MRIs and help plan personalized treatments for neurological disorders like Alzheimer's disease.

Neurological Disorder Diagnostics Market Insights, By Disease Indication: Genetic Neurological Disorder contribute the highest share of the market owing to its increased awareness & diagnostic demand.

Genetic Neurological Disorder expected to hold largest market share of 43.5% in 2026. Next-generation sequencing, whole genome, and exome analysis are making it easier to find inherited conditions, which is increasing the need for genetic tests for neurological disorders. Growing awareness of the genetic basis of diseases such as Alzheimer’s, Parkinson’s, and epilepsy drives early testing and personalized care. These tests have turned into a normal part of hospital and specialized laboratory work, and AI-powered tools help doctors understand the results. Further funding for research, more clinical trials, and the creation of gene-targeted therapies all speed up the use and development of genetic neurological diagnostics. In January 2026, Metropolis Healthcare Limited opened its Centre of Genomics in India. The center uses Illumina's NovaSeq™ X Series technology to improve precision diagnostics and genomic research.

Neurological Disorder Diagnostics Market Insights, By End User: Hospitals & Clinics contribute the highest share of the market owing to its integrated care and multidisciplinary teams.

Hospitals & Clinics acquired the prominent market share of 42.9% in 2026. Hospitals and clinics are boosting the neurological disorder diagnostics market by delivering comprehensive services, such as advanced imaging, genetic testing, and laboratory analyses within a single facility. Rising patient volumes and the urgent requirement to assess neurological conditions, including acute cases, increase demand. Multidisciplinary care teams enhance diagnostic precision and treatment planning. By adopting modern technologies, expanding clinical offerings, and catering to patient preferences for centralized care, these providers drive greater adoption. Increased awareness of early detection further strengthens market growth.

Regional Insights 

To learn more about this report, Download Free Sample

North America Neurological Disorder Diagnostics Market Trends

North America dominates the overall market with an estimated share of 41.80% in 2026. Widespread use of advanced imaging technologies, genetic testing, and AI-powered diagnostic tools is driving the North American neurological disorder diagnostics market. Hospitals and specialized clinics are integrating these solutions to enhance early detection and deliver personalized care. Robust healthcare infrastructure, substantial research investment, and active involvement of leading industry players are accelerating innovation and expanding market reach. Patients and healthcare providers are becoming more aware of neurological diseases, and supportive reimbursement policies are making it easier for more people to get comprehensive diagnostic services in the area. In September 2025, Beckman Coulter Diagnostics released the first fully automated Brain-derived Tau (BD-Tau) research-use-only immunoassay in the industry. It can be used on the DxI 9000 Immunoassay Analyzer and Access 2 Analyzer.

Asia Pacific Neurological Disorder Diagnostics Market Trends

The neurological disorder diagnostics market is growing steadily due to hospitals, clinics, and diagnostic centers in Asia Pacific using advanced imaging, genetic testing, and AI-powered technologies. The growing number of neurological and neurodegenerative disorders, along with greater numbers of individuals being aware of healthcare, drives up the need for early and accurate diagnosis. To make it easier for people to get diagnostic services, governments and healthcare providers are building more infrastructure and putting funds into research and development. Emerging economies are using new technologies to improve patient care and make the region's neurological diagnostics stronger.

United States Neurological Disorder Diagnostics Market Trends

Healthcare providers in the US are helping the neurological disorder diagnostics market grow by using advanced imaging, genetic testing, and AI-enabled tools in their work. As neurological and neurodegenerative disorders become more prevalent, the need for accurate and early diagnosis grows. Strong healthcare systems, significant amounts of research, and active involvement from major players in the industry all help new technologies spread easily and encourage innovation. More patients and doctors are aware of comprehensive diagnostic services, and insurance and reimbursement policies that support them make them increasingly accessible across the country.

For instance, in March 2025, neuropacs™ Corp. has announced positive results from a prospective multicenter study evaluating its AI technology for diagnosing Parkinson’s disease and atypical parkinsonism.

India Neurological Disorder Diagnostics Market Trends

The neurological disorder diagnostics market is growing considering hospitals, clinics, and diagnostic centers in India are using new imaging technologies, genetic testing, and AI-powered diagnostic tools. The growing number of neurological and neurodegenerative diseases, along with more people being aware of healthcare, drives up the need for early and accurate diagnosis. Access to diagnostic services is getting better through the expansion of healthcare infrastructure, government programs, and more money going into research. To improve patient care and India's neurological diagnostics capabilities, private providers and new urban centers are combining advanced technologies. In January 2026, Iswarya Hospital, a multi-specialty quaternary care facility in OMR, Chennai, opened a specialized clinic to find out exactly what causes giddiness, dizziness, vertigo, and balance problems.

End-User Feedback and Unmet Needs in the Neurological Disorder Diagnostics Market

• Demand for Early and Accurate Diagnosis: End-users emphasize the need for faster, more precise diagnostic tools to detect neurological disorders at an early stage. Delayed diagnosis often leads to progression of disease and limited treatment options, highlighting the necessity for high-sensitivity imaging, genetic testing, and biomarkers that can provide timely and reliable results.
• Integration of Advanced Technologies: Clinicians and hospitals report a growing need for seamless integration of AI, machine learning, and digital tools into diagnostic workflows. Many existing systems lack interoperability or advanced analytical capabilities, slowing decision-making and workflow efficiency, creating a demand for solutions that combine imaging, lab tests, and patient data effectively.
• Accessibility and Affordability Challenges: Patients and smaller clinics highlight barriers such as high costs of advanced diagnostics and limited availability in rural or semi-urban areas. End-users seek affordable testing options, decentralized services, and wider distribution of diagnostic centers to ensure timely access to neurological evaluations across diverse populations.

Neurological Disorder Diagnostics Market Trend

Advancement in Imaging Technologies

The market is increasingly shaped by innovations in neuroimaging, including high-resolution MRI, PET, CT, and hybrid systems. These tools enable earlier and more accurate detection of neurological and neurodegenerative disorders. Integration of AI-assisted image analysis allows clinicians to identify subtle abnormalities, track disease progression, and improve diagnostic confidence. Hospitals and specialized clinics are upgrading equipment to meet patient demand, while research institutions leverage advanced imaging for clinical studies, driving broader adoption and expanding diagnostic capabilities.

Growth of Genetic and Molecular Diagnostics

Genetic testing and molecular diagnostics are gaining prominence in detecting hereditary and complex neurological disorders. Techniques such as whole genome sequencing, exome sequencing, and biomarker profiling enable identification of disease-causing mutations and personalized treatment planning. Clinicians and laboratories increasingly rely on these tests for early diagnosis, risk assessment, and patient stratification in clinical trials. Rising awareness of genetic contributions to conditions like Alzheimer’s, Parkinson’s, and epilepsy further boosts demand for advanced molecular diagnostic solutions.

Market Report Scope 

Neurological Disorder Diagnostics Market News

• In January 2025, LVIS Corp has launched the cloud-based Neuromatch Access platform, a software-as-a-service solution that enables neurologists and medical professionals to review, interpret, and analyze electroencephalogram (EEG) data.
• In July 2025, CereMark Pharma initiated a Phase III clinical trial of its PET imaging agent, F-18 flornaptitril, at Endeavor Health’s Neurosciences Institute in Evanston, Illinois. F-18 flornaptitril is a PET radiotracer designed to simultaneously detect brain tau aggregates and beta-amyloid plaques within a single imaging scan.

Analyst Opinion (Expert Opinion)

• The neurological disorder diagnostics market is currently at an inflection point where traditional diagnostic pathways are being upended by advanced, data‑driven methodologies. Adoption metrics indicate that imaging continues to dominate clinical workflows, with magnetic resonance imaging (MRI) constituting approximately 30 % of diagnostic tool utilization globally due to its superior structural resolution, particularly in detecting brain tumors, stroke, and demyelinating disorders such as multiple sclerosis. Meanwhile, artificial intelligence (AI) integration is rapidly gaining traction; insights from industry reports reveal that roughly 40 % of diagnostic manufacturers are now embedding AI capabilities into their platforms to enhance diagnostic precision and throughput, especially within complex neurological profiles where manual interpretation is insufficient.
• The shift toward molecular and genetic diagnostics should not be understated. Clinically validated neurogenetic assays — such as rapid exome sequencing now deployed in over 42 % of tertiary care hospitals — underscore a deliberate move toward early, etiological diagnosis over symptom‑based categorization, which historically dominated neurology practice.
• A concrete example of diagnostic evolution is observable in Alzheimer’s disease. New blood‑based biomarkers measuring phosphorylated tau (pTau181) are being implemented outside traditional cerebrospinal fluid sampling and PET imaging protocols — a significant clinical milestone that promises to improve patient comfort and access while reducing diagnostic bottlenecks. This mirrors broader industry momentum toward minimally invasive, scalable tools capable of supporting early detection and monitoring.
• Despite these advances, the market is contending with entrenched disparities in clinical adoption. Highly sophisticated neurodiagnostic tools remain concentrated in developed healthcare systems, and their deployment in resource‑limited settings lags considerably. Furthermore, while AI systems have demonstrated significant promise — including reductions in image interpretation time and increased detection sensitivity — integrating these algorithms into standard practice still demands robust validation, regulatory harmonization, and clinician trust.

Market Segmentation

• By Technology
  • Imaging
  • In Vitro Diagnostics
• By Disease Indication
  • Genetic Neurological Disorders
  • Immunological Neurological Disorders
  • Paraneoplastic Syndrome
  • Paraproteinemic Neuropathies
  • Others
• By End User
  • Hospitals & Clinics
  • Diagnostic Centers
  • Ambulatory Care Centers
• By Regional Insights
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Siemens Healthineers
  • Koninklijke Philips N.V.
  • General Electric Company
  • Esaote SpA
  • NeuroLogica Corporation
  • Masimo Corporation
  • York Instruments Ltd.
  • Neusoft Medical Systems
  • Canon Medical Systems Corporation

Sources

Primary Research interviews

• Interviews with neurologists, radiologists, and clinical lab managers
• Discussions with hospital administrators and diagnostic center directors
• Conversations with genetic counselors and neurogenetic specialists

Databases

• PubMed
• ClinicalTrials.gov
• WHO Global Health Observatory
• National Center for Biotechnology Information (NCBI)

Magazines

• Neurology Today
• Brain & Life Magazine
• The Scientist

Journals

• Journal of Neurology, Neurosurgery & Psychiatry
• NeuroImage
• Frontiers in Neurology
• Lancet Neurology

Newspapers

• The New York Times – Health Section
• The Guardian – Science & Health
• The Washington Post – Health & Science

Associations

• World Federation of Neurology (WFN)
• American Academy of Neurology (AAN)
• European Federation of Neurological Societies (EFNS)
• Parkinson’s Foundation

Public Domain sources

• National Institutes of Health (NIH) Reports
• Centers for Disease Control and Prevention (CDC) Data
• Food and Drug Administration (FDA) Publications
• Government health ministry reports

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 8 years